Home / Healthcare / Healthcare News Update: Amgen (NASDAQ: AMGN)

Healthcare News Update: Amgen (NASDAQ: AMGN)

On Friday, Shares of Amgen (NASDAQ: AMGN) lost -0.92% to $156.51. During the day, the lowest price at which share is traded was $156.35 and hit the highest price at $158.58. The stock’s institutional ownership stands at 81%.

Amgen (NASDAQ: AMGN) recently declared voting results from the Company’s yearly conference of Stockholders, held in Westlake Village, Calif. Approximately 90.00% of exceptional shares were represented at the discussion.

The director nominees David Baltimore, Robert A. Bradway, François de Carbonnel, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Charles M. Holley Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar and R. Sanders Williams were each re-elected to Amgen’s Board of Directors. Each director received at least 95.00% of the votes cast “For.” Also at the discussion, retiring directors Frank J. Biondi Jr. and Judith C. Pelham were recognized for their contributions while on the Board. With the re-election of all of the director nominees and Mr. Biondi and Ms. Pelham’s retirement, Amgen currently has 13.00 directors.

With approximately 98.00% of the votes cast “For,” stockholders ratified Ernst & Young LLP as Amgen’s independent registered public accountants for the year finishing Dec. 31, 2017.

Stockholders approved, on an advisory basis, the named executive officer compensation, commonly known as “Say on Pay.” The non-binding proposal gives stockholders the chance to endorse or not endorse Amgen’s executive pay programs and policies. Say on Pay received approximately 95.00% of the votes cast “For” the proposal. In connection with this advisory vote, stockholders voted that executive compensation should be voted on yearly, with approximately 91.00 percent of the votes cast.

The stockholder proposal to adopt majority votes cast standard for matters presented by stockholders did not pass, receiving approximately 6 percent of the votes cast “For” the proposal.

Technical Analysis:

AMGN has market value of $115.76 billion while its EPS was booked as $10.55 in the last 12 months. The stock has 735.40 million shares outstanding. In the profitability analysis, the company has gross profit margin of 81.90% while net profit margin was 34.40%. Beta value of the company was 1.37; beta is used to measure riskiness of the security.

Analyst recommendation for this stock stands at 2.40.

Check Also

Healthcare Updates: Nektar Therapeutics (NASDAQ: NKTR)

Nektar Therapeutics (NASDAQ: NKTR) recently declared positive preclinical results for NKTR-358, a first-in-class resolution therapeutic …